Zur Kurzanzeige

dc.creatorPapagiannis D., Thireos E., Mariolis A., Katsioulis A., Gartzonika K., Malliaraki N., Agnantis C., Tsaras K., Malli F., Rouka E.C., Tsiaousi I., Symvoulakis E.K., Rachiotis G., Gourgoulianis K.I.en
dc.date.accessioned2023-01-31T09:43:19Z
dc.date.available2023-01-31T09:43:19Z
dc.date.issued2022
dc.identifier10.3390/vaccines10091511
dc.identifier.issn2076393X
dc.identifier.urihttp://hdl.handle.net/11615/77703
dc.description.abstractThe reported cases of pertussis vary considerably globally. In the present nationwide study, we aimed to record the Bordetella pertussis prevalence in Greece by measuring serum IgG specific antibody levels to pertussis toxin (anti-PT IgG). General practitioners and laboratories participated in this study from 12 regions of Greece. A geographically stratified sampling plan based on regional units (NUTS level 2) was applied in order to produce a representative sample, taking into consideration age group (30–39, 40–49, 50–59, 60–69, 70–79 and 80+) and sex. In total, 1169 subjects participated in the study. The percentage of participants with anti-PT IgG antibodies higher than 50 IU/mL was 3.7%. The levels of anti-PT IgG antibodies of total sample ranged between 1.46 IU/mL to 126.60 IU/mL, with mean 17.74 IU/mL and standard deviation 14.03 U/mL (p-value < 0.001). The total seroprevalence of Greek regions for pertussis disease varied significantly among prefectures. The region with the highest seroprevalence was Peloponnese 21.3%, followed by the region of Central Greece 15.3%. The proportion of adults who have pertussis specific antibodies <50 IU/mL has been >90%, suggesting that a large number of adults may be vulnerable to infection of pertussis despite well-established vaccination programs in Greece. Despite the fact that vaccination reduced the number of reported pertussis cases in the last decades in Greece, our seroprevalence study may indicate that the herd immunity level among Greek adults is suboptimal. © 2022 by the authors.en
dc.language.isoenen
dc.sourceVaccinesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85138648076&doi=10.3390%2fvaccines10091511&partnerID=40&md5=aebc50c55526a46933b5f012c57688e7
dc.subjectimmunoglobulin G antibodyen
dc.subjectpertussis toxinen
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectBordetella pertussisen
dc.subjectchi square testen
dc.subjectconfidence intervalen
dc.subjectenzyme linked immunosorbent assayen
dc.subjectfemaleen
dc.subjectFisher exact testen
dc.subjectgeneral practitioneren
dc.subjectGreeceen
dc.subjecthealth care facilityen
dc.subjectherd immunityen
dc.subjecthumanen
dc.subjectimmunizationen
dc.subjectimmunoglobulin blood levelen
dc.subjectKruskal Wallis testen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectnonhumanen
dc.subjectpertussisen
dc.subjectpopulationen
dc.subjectprevalenceen
dc.subjectprivate hospitalen
dc.subjectpublic healthen
dc.subjectpublic hospitalen
dc.subjectsample sizeen
dc.subjectsensitivity and specificityen
dc.subjectseroprevalenceen
dc.subjectvaccinationen
dc.subjectMDPIen
dc.titlePertussis Prevalence in Adult Population in Greece: A Seroprevalence Nationwide Studyen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige